XBiotech Inc.
XBITAs of the close on Sep 25, 2026
Price
$2.17
Market cap
$66.2M
P/E (diluted TTM)
—
Per-share earnings are not available for each of the last four quarters
EPS (TTM)
—
Per-share earnings are not available for each of the last four quarters
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How XBiotech Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: XBiotech Inc. — 10-K filed Mar 15, 2024
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 13 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Nov 12, 2025. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Arax Advisory Partners | 2026-03-31 | 15 | Not shown | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2026-03-31 | 105,540 | Not shown | SEC filing |
| JONES FINANCIAL COMPANIES LLLP | 2026-03-31 | 370 | Not shown | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 18,691 | Not shown | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 293,104 | Not shown | SEC filing |
| STATE STREET CORP | 2026-03-31 | 73,006 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 96 | Not shown | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2026-03-31 | 22,438 | Not shown | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 37 | Not shown | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 17,901 | Not shown | SEC filing |
| RBF Capital, LLC | 2026-03-31 | 198,501 | Not shown | SEC filing |
| UBS Group AG | 2026-03-31 | 5,035 | Not shown | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 1,189 | Not shown | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 76,087 | Not shown | SEC filing |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 98,447 | Not shown | SEC filing |
| DIMENSIONAL FUND ADVISORS LP | 2026-03-31 | 36,053 | Not shown | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 165,554 | Not shown | SEC filing |
| Caitong International Asset Management Co., Ltd | 2026-03-31 | 11 | Not shown | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 27,164 | Not shown | SEC filing |
| NATIONAL BANK OF CANADA /FI/ | 2026-03-31 | 25,000 | Not shown | SEC filing |
- Each value is checked against XBiotech Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Larson Financial Group LLC: 21 shares reported 2025-12-31; 21 shares reported 2026-03-31.
- RHUMBLINE ADVISERS: 928 shares reported 2025-12-31; 928 shares reported 2026-03-31.
- BANK OF AMERICA CORP /DE/: 35,895 shares reported 2025-12-31; 36,689 shares reported 2026-03-31.
- Pinnacle Financial Partners, Inc.: 11,796 shares reported 2025-12-31; 11,796 shares reported 2026-03-31.
- Connor, Clark & Lunn Investment Management Ltd.: 30,229 shares reported 2025-12-31; 28,663 shares reported 2026-03-31.
- JANE STREET GROUP, LLC: 69,738 shares reported 2025-12-31; 60,100 shares reported 2026-03-31.
- Empowered Funds, LLC: 59,547 shares reported 2025-12-31; 59,547 shares reported 2026-03-31.
- Squarepoint Ops LLC: 64,004 shares reported 2025-12-31; 41,214 shares reported 2026-03-31.
- Bank of New York Mellon Corp: 48,451 shares reported 2025-12-31; 39,355 shares reported 2026-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 221,121 shares reported 2025-12-31; 231,020 shares reported 2026-03-31.
- Optiver Holding B.V.: 8 shares reported 2025-12-31; 8 shares reported 2026-03-31.
- McIlrath & Eck, LLC: 753 shares reported 2025-12-31; 753 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
16 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among XBiotech Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2020-12-18 · BAY STREET FINANCIAL S.A.: Larger than 48 of the 49 other insider sales of Common Stock on file. SEC filing
- 2020-12-02 · BAY STREET FINANCIAL S.A.: Larger than 45 of the 49 other insider sales of Common Stock on file. SEC filing
- 2020-11-19 · MCKENZIE W THORPE: Larger than 46 of the 49 other insider sales of Common Stock on file. SEC filing
- 2020-02-19 · BAY STREET FINANCIAL S.A.: Larger than all 49 other insider sales of Common Stock on file. SEC filing
- 2018-10-04 · MCKENZIE W THORPE: Larger than 47 of the 49 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2024-01-03 | SIMARD JOHN · Chief Executive Officer | Convertible Loan Agreement | P — Open market or private purchase | +2,470,355 | 10,000,000.00 | SEC filing |
| 2021-10-18 | SIMARD JOHN · Chief Executive Officer | Common Stock | S — Open market or private sale | −33,000 | 13.07 | SEC filing |
| 2021-10-15 | SIMARD JOHN · Chief Executive Officer | Common Stock | S — Open market or private sale | −17,000 | 13.32 | SEC filing |
| 2021-10-14 | SIMARD JOHN · Chief Executive Officer | Common Stock | S — Open market or private sale | −21,125 | 12.90 | SEC filing |
| 2021-10-13 | SIMARD JOHN · Chief Executive Officer | Common Stock | S — Open market or private sale | −10,875 | 12.83 | SEC filing |
| 2021-10-12 | SIMARD JOHN · Chief Executive Officer | Common Stock | S — Open market or private sale | −18,000 | 12.77 | SEC filing |
| 2021-10-07 | SIMARD JOHN · Chief Executive Officer | Common Stock | S — Open market or private sale | −39,286 | 12.45 | SEC filing |
| 2021-10-06 | SIMARD JOHN · Chief Executive Officer | Common Stock | S — Open market or private sale | −10,714 | 12.53 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-10-01 | Troy Tevi David · Director | Director Stock Option | A — Grant, award, or other acquisition | +56,000 | SEC filing |
| 2025-10-01 | Rademaker Craig Evan · Director | Director Stock Option | A — Grant, award, or other acquisition | +92,104 | SEC filing |
| 2025-10-01 | Soffer David Spencer · Director | Director Stock Option | A — Grant, award, or other acquisition | +51,000 | SEC filing |
| 2025-10-01 | Kuendig Thomas Martin · Director | Director Stock Option | A — Grant, award, or other acquisition | +79,115 | SEC filing |
| 2025-03-17 | SIMARD JOHN · Chief Executive Officer | Stock Option | A — Grant, award, or other acquisition | +1,026,228 | SEC filing |
| 2024-06-20 | MCKENZIE W THORPE · Director, 10% owner | Director Stock Option | A — Grant, award, or other acquisition | +37,500 | SEC filing |
| 2024-06-20 | MacAdam Donald H. · Director | Director Stock Option | A — Grant, award, or other acquisition | +37,500 | SEC filing |
| 2024-06-20 | Waldin Jan-Paul · Director | Director Stock Option | A — Grant, award, or other acquisition | +37,500 | SEC filing |
Showing 8 of 25 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-01-31 | SIMARD JOHN · Chief Executive Officer | Convertible Loan Agreement | J — Other acquisition or disposition | −2,470,355 | SEC filing |
| 2021-01-28 | SIMARD JOHN · Chief Executive Officer | Stock Options | W — Acquisition or disposition by will or laws of descent | −89,260 | SEC filing |
| 2021-01-28 | SIMARD JOHN · Chief Executive Officer | Stock Options | W — Acquisition or disposition by will or laws of descent | −500,000 | SEC filing |
| 2021-01-28 | SIMARD JOHN · Chief Executive Officer | Stock Options | W — Acquisition or disposition by will or laws of descent | −13,484 | SEC filing |
| 2021-01-28 | SIMARD JOHN · Chief Executive Officer | Stock Options | W — Acquisition or disposition by will or laws of descent | −150,000 | SEC filing |
| 2021-01-28 | SIMARD JOHN · Chief Executive Officer | Stock Options | W — Acquisition or disposition by will or laws of descent | −1,875 | SEC filing |
| 2020-09-18 | SIMARD JOHN · Chief Executive Officer | Common Stock | J — Other acquisition or disposition | −500,000 | SEC filing |
| 2020-02-12 (amended) | MCKENZIE W THORPE · Director, 10% owner | Common Stock | D — Disposition to the issuer | −1,462,636 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.